| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $70.7M | -24.6% |
| SG&A Expense | $26.1M | -21.7% |
| Operating Income | -$100.9M | +19.6% |
| Net Income | -$96.9M | +17.6% |
| EPS (Basic) | -$2.52 | +18.4% |
| EPS (Diluted) | -$2.52 | +18.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $48.4M | -46.5% |
| Short-term Investments | $2.8M | -95.0% |
| Current Assets | $54.8M | -64.6% |
| Total Assets | $58.8M | -63.3% |
| Current Liabilities | $13.1M | -54.5% |
| Total Liabilities | $13.9M | -53.6% |
| Stockholders' Equity | $44.8M | -65.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$97.2M | +3.6% |
| Capital Expenditures | $33K | -89.1% |
| Investing Cash Flow | $54.8M | -42.3% |
| Financing Cash Flow | $194K | -60.6% |
| Free Cash Flow | -$97.2M | +3.8% |